ClinicalTrials.gg
RecruitingNCT06064890ASPIRE-FTDUpdated Aug 13, 2026

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

A Phase 1/2 interventional study of Intrathalamic AAV.PGRN administration and Intrathalamic AVB-101 in Frontotemporal Dementia, FTD and FTD-GRN, sponsored by AviadoBio Ltd. Recruiting at 19 sites in 9 countries. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by AviadoBio Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
30 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement. These symptoms result from below normal levels of a protein called progranulin (PGRN) in the brain, which leads to the death of nerve cells (neurons), affecting the brain's ability to function.

The main questions that the study aims to answer are:

  1. Is a one-time treatment with AVB-101 safe for patients with FTD-GRN?
  2. Does a one-time treatment with AVB-101 restore PGRN levels to at least normal levels?
  3. Could AVB-101 work as a treatment to slow down or stop progression of FTD-GRN?

In this study there is no placebo (a dummy pill or treatment used for comparison purposes), so all participants will receive a one-time treatment of AVB-101 delivered directly to the brain, with follow-up assessments for 5 years.

02

Conditions studied

  • Frontotemporal Dementia
  • FTD
  • FTD-GRN
  • Dementia, Frontotemporal

Keywords

  • Gene Therapy
  • AAV
  • Intrathalamic
  • Intraparenchymal
  • Progranulin
  • Behavioral Variant FTD
  • Primary Progressive Aphasia
  • PGRN
  • Granulin
  • Dementia
  • Dementia Gene Therapy
  • AAV9
03

In context

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

This study's planned enrollment of 18 is below the median of 50 across 128 interventional studies indexed under Frontotemporal Dementia.

Browse Frontotemporal Dementia studies →

Lead sponsor

This is the only study on the registry with AviadoBio Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 30 to 75 years of age
  • Carriers of a pathogenic GRN mutation
  • FTD as evidenced by CDR + NACC FTLD global score of 0.5, 1.0, or 2.0
  • Presence of 1 or more of the criteria for diagnosis of possible bvFTD or PPA
  • Able and willing to comply with all procedures and the study visit schedule
  • Able and willing to give written prior to study participation, and agree to designate a legal representative to act on their wishes to continue participation should they lose capacity to consent at some point during the study OR If, in the Investigator's opinion, the subject lacks capacity to consent, written informed consent of their legal representative must be obtained in accordance with local laws, regulations, and/or customs. In countries where local laws, regulations, and/or customs do not permit subjects who lack capacity to consent to participate in this study, these subjects will not be enrolled
  • An identified, informed study partner who is able and willing to support the participant in the study and to provide assessments of the participant during the study

Exclusion criteria

Exclusion Criteria:

  • Severe dementia, defined as CDR + NACC FTLD global score of 3.0, or other symptoms that preclude the ability to comply with study procedures and/or pose unacceptable safety risk to the subject
  • Any concurrent disease that may cause cognitive impairment unrelated to mutations in the GRN gene, such as other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin B12 deficiency
  • abnormality on MRI at Screening considered to be a to Intrathalamic infusion
  • Surgically significant pattern of brain atrophy on MRI at Screening that interferes with planned neurosurgical trajectory
  • Previous treatment with any gene or cell therapy
  • Previous treatment with any medicinal product (IMP) within 60 days or 5 half-lives (whichever is longer) prior to study drug treatment
  • Concomitant disease, any clinically significant laboratory abnormality, or treatment which, in the opinion of the Investigator, may pose an unacceptable safety risk to the participant or interfere with study conduct or the participant's ability to comply with study procedures including neurosurgical administration under anesthesia
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (dose 1)

    Initial dose

    Procedure: Intrathalamic AAV.PGRN administration · Genetic: Intrathalamic AVB-101

  • Experimental
    Cohort 2 (dose 2)

    Escalated dose

    Procedure: Intrathalamic AAV.PGRN administration · Genetic: Intrathalamic AVB-101

  • Experimental
    Cohort 3 (dose 3)

    Additional dose

    Procedure: Intrathalamic AAV.PGRN administration · Genetic: Intrathalamic AVB-101

  • Experimental
    Cohort 4 (dose 4)

    Additional dose

    Procedure: Intrathalamic AAV.PGRN administration · Genetic: Intrathalamic AVB-101

Interventions

  • ProcedureIntrathalamic AAV.PGRN administration

    One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain

  • GeneticIntrathalamic AVB-101

    AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.

06

What researchers measure

Primary outcomes

  1. Number and incidence of AEs and SAEs

    Type and incidence of adverse events

    Time frame: Up to week 26

  2. Change from baseline in the Mini-Mental State Examination (MMSE)

    Mini-Mental State Examination (MMSE) is a global assessment of cognitive status. Score range 0-30; higher scores reflect better cognitive function. Change in MMSE score from baseline visit to post-treatment visit will be assessed.

    Time frame: Up to week 12

  3. Incidence of treatment emergent suicidal ideation or behavior

    The Columbia-Suicide Severity Rating Scale (C-SSRS) is an assessment tool that evaluates suicidal ideation and behavior. C-SSRS will be measured at each visit to assess for absence/presence of suicidal ideation and/or behavior.

    Time frame: 26 week initial, 5-year total follow-up period

  4. Incidence of treatment-emergent clinically significant abnormalities in clinical examination findings

    Time frame: 5-year total follow-up period

  5. Incidence of treatment-emergent clinically significant abnormalities in safety laboratory values

    Time frame: 5-year total follow-up period

  6. Change from baseline in brain structure

    Assessed by presence of any clinically significant MRI findings at post treatment visits including brain swelling or bleeding

    Time frame: 5-year total follow-up period

Secondary outcomes

  1. Change from baseline in PGRN protein levels in CSF and blood

    Change over time in level of PGRN

    Time frame: 26-week initial and 5-year total follow-up period

  2. Change from baseline in NfL levels in CSF and blood

    Change over time in level of NfL

    Time frame: 26-week initial and 5-year total follow-up period

  3. Change from baseline in CDR + NACC FTLD-SB score

    The Clinical Dementia Staging Instrument (CDR) plus National Alzheimer's Coordinating Center Frontotemporal Degeneration domains (NACC FTLD) was developed as a way to improve characterization of cognitive and global function in patients with FTLD. The CDR+NACC FTLD score will capture patients' disease status. CDR+NACC FTLD Sum of Boxes (SB) score refers to the sum of the scores of each domain (sum of boxes) that ranges from 0 to 24.

    Time frame: 5-year total follow-up period

  4. Time to achieve clearance of vector genomes

    Measured in plasma and semen (males only)

    Time frame: Up to week 26

  5. Change from baseline in brain volumes

    Calculation based upon 3DT1 MRI scans

    Time frame: 5-year total follow-up period

  6. Change from baseline in AAV9 immunogenicity in blood

    Measured by level of antibodies and ELISPOT to AAV9 capsid

    Time frame: 5-year total follow-up period

  7. Change from baseline in AAV9 immunogenicity in CSF

    Measured by level of antibodies to AAV9 capsid

    Time frame: 5-year total follow-up period

  8. Change from baseline in PGRN immunogenicity in CSF

    Measured by level of antibodies to PGRN protein

    Time frame: 5-year total follow-up period

  9. Change from baseline in PGRN immunogenicity in blood

    Measured by level of antibodies and ELISPOT to PGRN protein

    Time frame: 5-year total follow-up period

  10. Change in Caregiver Global Impression of Change (CaGI-C)

    Global impression of change as assessed by the caregiver. The CaGI-C is a 7 point scale where 1= very much improved, 7= very much worse.

    Time frame: 5-year total follow-up period

  11. Change in Patient Global Impression of Change (PGI-C)

    Global impression of change as assessed by the patient. The PGI-C is a 7 point scale where 1= very much improved, 7= very much worse.

    Time frame: 5-year total follow-up period

  12. Change in Clinical Global Impression of Change (CGI-C)

    Global impression of change as assessed by the investigator (clinician). The CGI-C is a 7 point scale where 1= very much improved, 7= very much worse.

    Time frame: 5-year total follow-up period

  13. Change from baseline in GRN-specific Genetic Frontotemporal Initiative Cognitive (GENFI-Cog) composite score

    Calculated from the neuropsychological test battery that assesses various cognitive domains: language, attention/processing speed, executive function, verbal and visuospatial memory and social cognition. Scores from the neuropsychological test battery are converted using standard statistical methods into the composite score. The GRN specific composite score is expected to be more sensitive to detect changes in cognition that are associated with FTD, and will be compared to the baseline score. Lower scores indicate worse performance.

    Time frame: 5-year total follow-up period

  14. Change from baseline in GFAP levels in CSF and blood

    Change over time in level of GFAP

    Time frame: 5-year total follow-up period

07

Study locations

19 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Apr 2027, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Oct 3, 2023
StartActual
Aug 30, 2023
Primary completionEst.
Apr 1, 2027
CompletionEst.
Mar 21, 2030
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06064890
Lead sponsor
AviadoBio Ltd
Responsible party
Sponsor
First posted
Oct 3, 2023
Start date
Aug 30, 2023
Primary completion
Apr 1, 2027 (estimated)
Completion
Mar 21, 2030 (estimated)
Last update
Aug 13, 2026

Study contacts

AviadoBio Clinical Trials
Contact
clinicaltrials@aviadobio.com
+44 203-089-7917

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion